A

Amacathera

www.amacathera.ca link_icon

AmacaThera Inc. Market Research Report



Company Overview



Name, Mission of the company


  • Name: AmacaThera Inc.

  • Mission: Transforming therapeutics to make a difference in patient health. AmacaThera’s unique, injectable hydrogel platform provides localized, sustained drug delivery to improve patient outcomes across multiple therapeutic areas.


Founding Details


  • Founded: 2016

  • Founders:

  • Dr. Mike Cooke

  • Dr. Molly Shoichet


Key People


  • CEO: Dr. Mike Cooke

  • Chief Science Officer: Dr. Molly Shoichet

  • Vice President Business Development & General Manager: Mike Foorer

  • Board of Directors:

  • Paul Austin

  • Lu Han

  • Michelle Scarborough

  • Sara Secall


Headquarters


  • Location: MaRS Centre, West Tower, 661 University Ave Suite 1300, Toronto, ON M5G 0B7


Number of Employees


  • No information is available


Revenue


  • No information is available


Company Reputation


  • Known for: Development of advanced sustained release hydrogel formulations used for localized, sustained drug delivery in therapeutic areas like post-surgical pain management, cancer, and other hard-to-reach target areas.


Products



AMT-143


  • Description: An opioid-free formulation for the sustained release of an anesthetic.

  • Key Features:

  • Provides long-acting post-operative pain relief.

  • Delivered via the AmacaGel platform.

  • Aims to reduce reliance on opioids in post-surgical pain management.


AmacaGel Platform


  • Description: A proprietary, injectable hydrogel platform used to deliver localized therapeutics.

  • Key Features:

  • Long-lasting release window for sustained delivery.

  • Adaptable to multiple therapeutic applications including small molecules, growth factors, antibodies, stem cells, and enzymes.

  • Simple hydrogel system for easy manufacturability.

  • Approved components with proven safety.

  • Flexible platform for various drug deliveries.

  • Convenient dosing through a pre-filled syringe.


Pipeline Products


  • Pain (Post-Operative): Local anesthetic formulation in a pre-filled syringe for sustained post-surgical pain relief.

  • Oncology (Solid Tumours): Anti-neoplastic agent in a pre-filled syringe for local management with reduced systemic toxicity.

  • Anti-Infectives (Surgical): Antibiotics in a pre-filled syringe for surgical site infection prophylaxis and management.

  • Fixed Dose Combo: Combos of small molecules and biologics for localized depot applications.

  • Smart Materials: Locally activated biologic therapies.


Recent Developments



Recent News


  • June 13th, 2024: RBCx features AmacaThera’s journey.

  • Details: Interview with Co-Founders Mike J. Cooke and Molly Shoichet, covering the original research and progress of AMT-143.


  • May 15th, 2024: AmacaThera doses First In Human Study to Evaluate AMT-143.

  • Details: Announced dosing of the first human subject with AMT-143 for non-opioid treatment of post-operative pain.


  • November 28th, 2023: Series A Extension to advance clinical development.

  • Details: Closed CAD$4.0 million financing round to accelerate clinical development of AMT-143 and multiple pipeline programs.


  • July 5th, 2023: Collaboration with University Health Network.

  • Details: Evaluating the economic impact of post-surgical opioid use with the development of AMT-143.


  • March 9th, 2023: First subjects dosed in Phase 1 Clinical Trial for AmacaGel™.

  • Details: Dosing subjects in a Phase 1 trial to investigate the safety of AmacaGel™.


  • January 4th, 2023: Recognized in QuickFire Challenge for Lung Cancer applications.

  • Details: Received grant funding from the Innovations for Vets QuickFire Challenge.


Partnerships


  • No detailed specific new partnerships found in the recent developments.


For more updates and detailed information, you can visit their official website or follow them on LinkedIn.



Contact Information:
  • Phone: 416-360-2094

  • Email: info@amacathera.ca

  • Headquarters: MaRS Centre, West Tower, 661 University Ave Suite 1300, Toronto, ON M5G 0B7